Blepharitis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Blepharitis Emerging Therapy and TPP Insights

Thelansis’s “Blepharitis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Blepharitis Overview

Blepharitis is a common condition characterized by a chronic inflammatory process of the lid margins and is often caused by dysfunction of the oil glands of the lids and/or secondary to other skin disorders like seborrheic dermatitis and rosacea. It presents with burning sensations and itchiness of the lids and eye irritation due to crust formation around the lid margins and grittiness or irritation of the eyes. It may be anterior or posterior and can also be secondary to other lid and eye disorders like styes and dry eye syndrome. It is diagnosed based on clinical examination of the lid and eye surface. Treatment of blepharitis involves long-term lid care measures like hot compress and lid cleaning. It also requires antibiotic and anti-inflammatory drug therapy. Blepharitis is not sight-threatening; however, it is a troublesome condition due to its long-term and recurrent nature.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
    • Pipeline analysis
    • Target patients for emerging therapies
    • Key companies
    • Key mechanism of actions
    • Launch date estimates, etc.
  • Clinical trial landscape analysis
    • Target patient segments
    • Trial endpoints
    • Trial design
    • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
    • Performance of key current therapies
    • Top areas of unmet needs
    • Opportunity sizing for key unmet needs
  • Target Product Profiles
    • Attributes and levels
    • Physician likelihood of prescribing
    • Expected patient shares
  • KOL insights on key emerging therapies
    • Level of awareness
    • Expected use / line of therapy
    • Extent to fulfil key unmet needs
    • KOL quotes


Read more: Blepharitis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Epidermodysplasia verruciformis (EV) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032

Image
Epidermodysplasia verruciformis (EV) is a rare, lifelong, cutaneous, autosomal recessive immune system disorder characterized by increased susceptibility to cutaneous human papillomavirus (HPV) infection beginning in childhood. The disease usually manifests during infancy (7.5% of cases), youth (61.5% of cases), or puberty (22% of cases) with the progressive development of hyperpigmented or hypopigmented flat wart-like papules, irregular reddish-brown plaques, seborrheic keratosis-like lesions and pityriasis Versicolor-like macules on the trunk, neck, face, dorsal hands, and feet. Loss-of-function mutations can cause EV in either of two adjacent genes, EVER1/TMC6 or EVER2/TMC8 (17q25.3), which code for membrane proteins that form a complex with the zinc transporter protein ZnT-1 in the ER membrane of keratinocytes. In epidermodysplasia verruciformis, two clinical presentations have been described. Flat-topped papules and plaques with a scaly surface and irregular borders that are white...
Read more